Evidence map›Paper›PMID 42491364›Full record

ReviewGenes & diseases2026

Therapeutic resistance in cancer: lncRNAs as modulators and targets for cancer therapy.

Ashiq Ali, Urooj Azmat, Aisha Khatoon, Bilal Murtaza, Kaynaat Akbar, Ziyi Ji, Urooj Irshad, Kinza Ishaque, Zhongjing Su

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ashiq AliSchool of Medical Sciences, Shandong Xiehe University, Jinan, Shandong, 250109, China.
Urooj AzmatDepartment of Zoology, Wildlife and Fisheries, Faculty of Sciences, University of Agriculture, Faisalabad, Punjab 38040, Pakistan.
Aisha KhatoonDepartment of Pathology, University of Agriculture, Faisalabad, Punjab 38040, Pakistan.
Bilal MurtazaSchool of Bioengineering, Dalian University of Science and Technology, Dalian, Liaoning 114319, China.
Kaynaat AkbarDepartment of Zoology, Wildlife and Fisheries, Faculty of Sciences, University of Agriculture, Faisalabad, Punjab 38040, Pakistan.
Ziyi JiDepartment of Histology and Embryology, Shantou University Medical College, Shantou, Guangdong 515041, China.
Urooj IrshadDepartment of Zoology, Faculty of Sciences, Superior University, Lahore 51000, Pakistan.
Kinza IshaqueDepartment of Pathology, University of Agriculture, Faisalabad, Punjab 38040, Pakistan.
Zhongjing SuDepartment of Histology and Embryology, Shantou University Medical College, Shantou, Guangdong 515041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic resistance continues to be a significant challenge in cancer treatment, often leading to tumor recurrence, metastasis, and limited therapeutic efficacy despite advancements in chemotherapy and radiotherapy. This resistance arises from complex molecular mechanisms that are influenced by various factors, including genetic alterations, epigenetic modifications, and cellular signaling. Recently, lncRNAs, a subclass of non-coding RNAs, have gained prominence for their essential role in driving cancer progression and mediating resistance to therapy. The resistance phenotype is shaped by lncRNAs through the regulation of key signaling pathways, DNA repair mechanisms, and cellular survival processes. For example, lncRNAs such as HOTAIR and MALAT1 are involved in the regulation of PI3K/AKT, EMT, and DNA repair pathways, and influence cell proliferation, apoptosis, and metastasis. These findings underscore the potential of lncRNAs as therapeutic targets. Targeting lncRNA-mediated pathways offers a promising approach to overcome resistance and enhance the efficacy of existing therapies. This review provides an in-depth analysis of the molecular mechanisms by which lncRNAs mediate resistance in various cancers, such as gastric cancer, lung cancer, breast cancer, and hepatocellular carcinoma. By focusing on the therapeutic potential of lncRNAs, we propose new avenues for overcoming resistance and improving treatment outcomes in cancer therapy.

Indexed as

Cancer treatmentChemotherapyLong non-coding RNAsRadiation therapyTherapeutic resistance

Identifiers

PMID42491364
PMCPMC13377446

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.